Key Points
- CEO Martine Rothblatt sold 4,000 shares on November 28 at an average price of $487.64 for total proceeds of $1,950,560, leaving her with 130 shares (a 96.85% reduction).
- The company has a market cap of $20.67 billion and a P/E of 18.19; United Therapeutics reported Q3 EPS of $7.16 (beating the $6.89 estimate) while revenue was $799.5 million, up 6.8% year‑over‑year but slightly below expectations.
- Analysts maintain a consensus rating of Moderate Buy with a $505 average price target, and several firms recently raised their targets and reiterated outperform/overweight views.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the business's stock in a transaction on Friday, November 28th. The stock was sold at an average price of $487.64, for a total transaction of $1,950,560.00. Following the completion of the transaction, the chief executive officer owned 130 shares in the company, valued at $63,393.20. This represents a 96.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
United Therapeutics Price Performance
NASDAQ:UTHR opened at $479.95 on Tuesday. The firm has a 50-day moving average of $448.96 and a two-hundred day moving average of $363.80. The stock has a market cap of $20.67 billion, a P/E ratio of 18.19, a PEG ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $492.62.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analysts' expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company's revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.39 earnings per share. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts have issued reports on UTHR shares. Royal Bank Of Canada upped their target price on United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research report on Thursday, October 30th. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 10th. Bank of America upped their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Oppenheimer increased their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research note on Friday, September 5th. Finally, Wells Fargo & Company raised their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an "equal weight" rating in a report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $505.00.
Check Out Our Latest Stock Analysis on United Therapeutics
Institutional Trading of United Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB lifted its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares during the last quarter. Chung Wu Investment Group LLC bought a new position in United Therapeutics in the second quarter worth about $29,000. Abich Financial Wealth Management LLC bought a new position in United Therapeutics in the third quarter worth about $44,000. SVB Wealth LLC acquired a new position in United Therapeutics in the first quarter valued at approximately $32,000. Finally, WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Institutional investors own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
